Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Taiwan Urges Stronger Trade Ties With Fellow Democracies, Rejects Economic Dependence on China 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
EU Recovery Fund Faces Bottlenecks Despite Driving Digital and Green Projects 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
